The prognosis of patients with advanced gastrointestinal cancer is extremely poor. Current chemotherapeutic regimens in gastric and colorectal cancer have low response rates and are often highly toxic. As a result there has been much interest in novel forms of therapy in an attempt to identify new therapeutic options which will be more effective in the treatment of these patients. Several different classes of drugs have received increasing attention during the last few years and merit further investigation.
In this issue of the journal Cascinu et al. present the results of a randomised trial in 107 patients with advanced gastrointestinal cancer refractory to chemotherapy comparing treatment with the somatostatin analogue octreotide with best supportive care only. Stratification for performance status and the primary tumour was carried out prior to randomisation. Octreotide was administered by subcutaneous injection (200 g, three times daily, 5 days per week) and was continued until there was disease progression, unacceptable toxicity or patient refusal with a median treatment duration of 12 weeks (range 6-32 weeks). Treatment with octreotide conferred a significant survival advantage with a median survival of 20 weeks in the active arm compared with 11 weeks in the control arm (P<0.0001). A previous trial which randomised 260 chemotherapy-naive patients in a similar way to a lower dose of subcutaneous octreotide (150 Mg, three times daily) had failed to demonstrate any difference in either survival or time to progression in the treatment arm (Krook et al., 1993) . The difference in outcome may be due to the different cohort of patients, with no exposure to chemotherapy in the latter group, or to the different dose intensity of octreotide. It is of interest that the significant survival advantage in the study by Cascinu et al. occurs in the absence of any objective response to octreotide consistent with two previous non-randomised trials which reported stabihsation of disease only (Klijn et al., 1990; Smith et al., 1992) . Furthermore, the latter study demonstrated that survival was markedly prolonged in those patients with pretreatment elevated gastrin levels, suggesting that this therapy could perhaps be further improved by targeting specific tumour subgroups. In a similar way, other hormonal manipulation could also be targeted to specific tumours depending on the receptor status of individual growth factors/hormones. The exact mechanism by which somatostatin exerts its anti-tumour effect is not known, but several different theories have been described.
Somatostatin is a naturally occurring antitrophic hormone which has many diverse functions throughout the body. It inhibits the release of gastrin and growth hormone and interacts with the secretion of epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) (Schally, 1988 (Reubi et al., 1994) . Since these receptors are sparse in normal gastrointestinal mucosa it is proposed that increased expression of the SSTR2 subtype may be tumour specific and play a role in tumour-host interactions.
There is now an abundance of experimental data to support the anti-mitogenic role of somatostatin both in vitro and in vivo. Somatostatin analogues inhibit the basal and gastrinstimulated growth of several human colonic cancer cell lines in vitro and cause significant growth delay in human colon cancer xenograft studies (Dy et al., 1992; Alonso et al., 1992) . Furthermore, the growth and development of hepatic metastases can be reduced by treatment with the somatostatin analogues SMS 201-995 (Nott et al., 1989) and RC-160 (Qin et al., 1992) , suggesting a more specific potential role in the treatment of hepatic metastases of colorectal origin. Somatostatin, however, is only one of a number of hormones which are known to interact with both normal and neoplastic gstrointestinal epithelial cells.
There is now increasing evidence that tumours arising from the gastrointestinal tract may be partly hormone dependent and that hormonal manipulation may have a role to play in the treatment of these tumours. The proliferation of normal gastrointestinal mucosa is controlled by a number of hormones and growth factors. Gastrin, a polypeptide hormone which is trophic for normal gastrointestinal tract epithelial cells (Johnson, 1977) , has been shown to promote the growth of human gastric and colon cancer cells in vitro (Watson et al., 1988) . Furthermore, gastrin stimulates the in vivo growth of 50% of gastric and colorectal carcinoma xenografts (Baldwin and Whitehead, 1994) . Despite this experimental evidence supporting the role of gastrin as a mitogen in gastric tumours in vitro and in vivo, there appears to be no evidence that it plays a role in the development of gastric adenocarcinoma. The prolonged hypergastrinaema associated with type A atrophic gastritis does not increase the incidence of either gastric or colorectal adenocarcinoma despite the 3-fold increase in gastric cancer in patients with pernicious anaemia (Brinton et al., 1989 (Radulovic et al.. 1992) . By using specific antagonists to the gastrin cholecystokinin and somatostatin receptors the gastrin-stimulated growth of gastrointestinal tumour cells in vitro can be inhibted (Watson et al., 1992) . Furthermore. alterations to gastrin secretion using the bombesin gastrin-releasing peptide antagonist RC-3095 or the somatostatin analogue RC-160 inhibit the growth of MKN45 human gastric carcinoma xenografts in nude mice (Pinski et al.. 1994) . It is paradoxical that another group of drugs which cause hypergastrinaemia secondary to their reduction in gastric acid output also have a putative anticancer role in gastrointestinal malignancy.
Cimetidine. a histamine-2 receptor antagonist. can reverse the histamine-stimulated growth of gastric cancer cells both in *itro and in vivo (Watson et al.. 1993) . Cimetidine also inhibits cellular proliferation and slows early tumour invasion in an animal model of carcinogen-induced colon cancer compatible with a role independent of a host cellular immune response (Adams et al.. 1993 (Yu et al., 1993) . This agent and other protective lectins merit further study as potential anti-cancer agents. and this may establish a way for dietary modification to influence the prevention of gastrointestinal cancer.
In conclusion, there are now several alternative treatment strategies which may be of benefit in the treatment of gastrointestinal cancers. Although there is much experimental evidence from both in vitro and in vivo studies to support these potential treatment options. further clinical trials are essential to establish the exact role of hormonal growth factor manipulation. histamine-2 receptor antagonists and dietary modification in the prevention and treatment of these tumours. but the evidence to date is extremely encouraging.
